PI-kinase inhibitors with anti-infective activity

US11091472B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Jeffrey S. Glenn · Palo Alto, US
• Michael A. Gelman · New York, US
• Brandon Tavshanjian · San Francisco, US
• Kevan M. Shokat · San Francisco, US
• Ingrid Choong · Palo Alto, US
• Mark Smith · Saffron Walden, GB

Key dates

• Filing date: Feb 24, 2017
• Grant date: Aug 17, 2021
• Expiry date: Feb 24, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.